Nirsevimab has just begun to combat infant RSV, and supply is not keeping up with demand.
Published: Nov. 1, 2023 at 4:32 PM AKDTFAIRBANKS, Alaska - Respiratory syncytial virus, or RSV, is a contagious virus with cold-like symptoms that can be pretty common during the winter months. For a typical, healthy adult this isn’t that big of an issue, but for small infants it can be a different story.
On October 23 the CDC announced that due to the shortage of nirsevimab, all orders to Alaska will be paused for the next two weeks. “Getting an immunization to prevent RSV is something that should be done when the infant is just very young, in the baby’s first week of life is when it’s recommended. The younger they are, the more they can be impacted by RSV,” explained Nacde.
RSV is the leading cause of hospitalization among infants in the United States. While an adult can often brush off the symptoms, children are far more at risk for the severe form.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
RSV cases in kids continue to rise in North Texas according to healthcare providersCook Children's and Children's Health said they have seen a big increase in Respiratory Syncytial Virus, or RSV in the last month.
Read more »
Doctors dealing with shortage of kids RSV prevention drugSupply is so tight, the CDC has advised doctors to prioritize certain patients.
Read more »
Cost of RSV shot raises concerns over accessibilityInsurance companies currently do not have to offer the RSV vaccine for free, placing the onus on patients and parents to cover its cost.
Read more »
GSK PLC Raises Guidance After RSV Vaccine Lifts EarningsGSK said it now expects adjusted operating profit to increase between 13-15% for the year after it reported a rise in net profit in the third quarter, mainly due to the U.S. launch of its Arexvy vaccine.
Read more »
GSK Boosts Profit Forecasts After ‘Outstanding’ RSV Vaccine LaunchI am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.
Read more »
GSK Boosts Profit Forecasts After ‘Outstanding’ RSV Vaccine LaunchI am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.
Read more »